Prevalence of HI antibody titer against rubella virus to determine the effect of mass vaccination in Tehran

Journal of Clinical Virology

Volumn 34, Issue 2, 2005, Pages 153-154

  Soleimanjahi, H ^a   Bamdad, T ^a   Fotouhi, F ^a   Roustai, M H ^a   Faghihzadeh, S ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Antibody titer; Haemagglutination inhibition (HI); Mass vaccination; Rubella

Indexed keywords

RUBELLA ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNE STATUS; IMMUNITY; MASS IMMUNIZATION; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; RUBELLA VIRUS; SERUM; STATISTICAL SIGNIFICANCE;

ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IRAN; MASS IMMUNIZATION; RUBELLA; RUBELLA VACCINE; RUBELLA VIRUS; SEROEPIDEMIOLOGIC STUDIES; TREATMENT OUTCOME;

EID: 24644466068     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2005.05.004     Document Type: Article

References (3)

1. CDC Expanded programmed on immunization (EPI): immunization schedules in the WHO eastern Mediterranean region Wkly Epidemiol Rec 71 1996 173 176
2. J. Chantler, J.S. Wolinsky, and A. Tingle Rubella virus D.M. Knipe P.M. Howley Field's virology 2001 Lippincott-Williams and Wilkins Philadelphia 963 990
3. S.E. Robertson, F.T. Cutts, R. Samuel, and J.L. Diaz-Ortega Control of rubella and congenital rubella syndrome (CRS) in developing countries. Part 2. Vaccination against rubella Bult WHO 75 1997 69 80